Matches in SemOpenAlex for { <https://semopenalex.org/work/W2600595343> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W2600595343 endingPage "TPS10099" @default.
- W2600595343 startingPage "TPS10099" @default.
- W2600595343 abstract "TPS10099 Background: PDGFRα is a receptor commonly overexpressed in STS. Olaratumab is a fully human IgG1 MAb which specifically binds to human PDGFRα and blocks PDGFR-mediated signaling pathways. Olaratumab demonstrated significant tumor inhibition as a monotherapy and in combination with standard chemotherapy in preclinical human sarcoma xenograft models. A Phase 1b/2 clinical trial for patients with advanced or metastatic STS is currently enrolling patients in 9 sites across the United States; approximately 45 patients have been randomized. Methods: In Phase 1b, patients received olaratumab (15 mg/kg) via intravenous infusion on Days 1 and 8 of each 21-day cycle and D (75 mg/m²) 1 hour after olaratumab on Day 1. Phase 1b was completed without encountering dose-limiting toxicities; enrollment into Phase 2 has begun. The primary endpoint of the Phase 2 portion is to compare progression-free survival in patients with advanced STS when treated with D plus olaratumab versus D alone. Planned enrollment goal for Phase 2 is 130 patients. Patients are required to be ≥ 18 years old with ECOG 0-2, have appropriate organ function and histologically confirmed, measurable, and advanced STS. There is no restriction on the number of prior therapies. Patients are randomized 1:1 to either D plus olaratumab (Arm A) at same dose/schedule as in Phase 1b or D alone (Arm B). All patients can receive dexrazoxane. Upon completion of 8 cycles, patients in Arm A continue with olaratumab monotherapy. Patients in Arm B who develop disease progression during or after treatment can subsequently receive olaratumab monotherapy. Patients are stratified to treatment arms according to PDGFRα expression (positive vs. negative), number of previous lines of treatment, sarcoma subtype, and ECOG performance status. Response assessment occurs every 6 weeks. Exploratory analyses include biomarkers of olaratumab pharmacodynamic activity including PDGF ligands, PDGFR downstream molecules, VEGF, and changes in vascularity of tumor specimens." @default.
- W2600595343 created "2017-04-07" @default.
- W2600595343 creator A5000987410 @default.
- W2600595343 creator A5003417999 @default.
- W2600595343 creator A5006913373 @default.
- W2600595343 creator A5019044309 @default.
- W2600595343 creator A5031037291 @default.
- W2600595343 creator A5031405616 @default.
- W2600595343 creator A5039301683 @default.
- W2600595343 creator A5066564429 @default.
- W2600595343 creator A5069022903 @default.
- W2600595343 creator A5074289499 @default.
- W2600595343 creator A5080338388 @default.
- W2600595343 creator A5083922162 @default.
- W2600595343 creator A5084743009 @default.
- W2600595343 creator A5087234749 @default.
- W2600595343 creator A5091098703 @default.
- W2600595343 creator A5091362508 @default.
- W2600595343 creator A5091848952 @default.
- W2600595343 date "2012-05-20" @default.
- W2600595343 modified "2023-09-26" @default.
- W2600595343 title "A phase Ib/II study evaluating the efficacy of doxorubicin (D) with or without a human anti-PDGFRα monoclonal antibody olaratumab (IMC-3G3) in the treatment of advanced soft tissue sarcoma (STS)." @default.
- W2600595343 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.tps10099" @default.
- W2600595343 hasPublicationYear "2012" @default.
- W2600595343 type Work @default.
- W2600595343 sameAs 2600595343 @default.
- W2600595343 citedByCount "1" @default.
- W2600595343 countsByYear W26005953432023 @default.
- W2600595343 crossrefType "journal-article" @default.
- W2600595343 hasAuthorship W2600595343A5000987410 @default.
- W2600595343 hasAuthorship W2600595343A5003417999 @default.
- W2600595343 hasAuthorship W2600595343A5006913373 @default.
- W2600595343 hasAuthorship W2600595343A5019044309 @default.
- W2600595343 hasAuthorship W2600595343A5031037291 @default.
- W2600595343 hasAuthorship W2600595343A5031405616 @default.
- W2600595343 hasAuthorship W2600595343A5039301683 @default.
- W2600595343 hasAuthorship W2600595343A5066564429 @default.
- W2600595343 hasAuthorship W2600595343A5069022903 @default.
- W2600595343 hasAuthorship W2600595343A5074289499 @default.
- W2600595343 hasAuthorship W2600595343A5080338388 @default.
- W2600595343 hasAuthorship W2600595343A5083922162 @default.
- W2600595343 hasAuthorship W2600595343A5084743009 @default.
- W2600595343 hasAuthorship W2600595343A5087234749 @default.
- W2600595343 hasAuthorship W2600595343A5091098703 @default.
- W2600595343 hasAuthorship W2600595343A5091362508 @default.
- W2600595343 hasAuthorship W2600595343A5091848952 @default.
- W2600595343 hasConcept C126322002 @default.
- W2600595343 hasConcept C126894567 @default.
- W2600595343 hasConcept C142724271 @default.
- W2600595343 hasConcept C143998085 @default.
- W2600595343 hasConcept C168563851 @default.
- W2600595343 hasConcept C203092338 @default.
- W2600595343 hasConcept C2776694085 @default.
- W2600595343 hasConcept C2778256501 @default.
- W2600595343 hasConcept C2778629024 @default.
- W2600595343 hasConcept C2781303535 @default.
- W2600595343 hasConcept C31760486 @default.
- W2600595343 hasConcept C71924100 @default.
- W2600595343 hasConceptScore W2600595343C126322002 @default.
- W2600595343 hasConceptScore W2600595343C126894567 @default.
- W2600595343 hasConceptScore W2600595343C142724271 @default.
- W2600595343 hasConceptScore W2600595343C143998085 @default.
- W2600595343 hasConceptScore W2600595343C168563851 @default.
- W2600595343 hasConceptScore W2600595343C203092338 @default.
- W2600595343 hasConceptScore W2600595343C2776694085 @default.
- W2600595343 hasConceptScore W2600595343C2778256501 @default.
- W2600595343 hasConceptScore W2600595343C2778629024 @default.
- W2600595343 hasConceptScore W2600595343C2781303535 @default.
- W2600595343 hasConceptScore W2600595343C31760486 @default.
- W2600595343 hasConceptScore W2600595343C71924100 @default.
- W2600595343 hasIssue "15_suppl" @default.
- W2600595343 hasLocation W26005953431 @default.
- W2600595343 hasOpenAccess W2600595343 @default.
- W2600595343 hasPrimaryLocation W26005953431 @default.
- W2600595343 hasRelatedWork W1830023854 @default.
- W2600595343 hasRelatedWork W1906474388 @default.
- W2600595343 hasRelatedWork W2027419421 @default.
- W2600595343 hasRelatedWork W2319265835 @default.
- W2600595343 hasRelatedWork W2402032689 @default.
- W2600595343 hasRelatedWork W2413552560 @default.
- W2600595343 hasRelatedWork W2516351805 @default.
- W2600595343 hasRelatedWork W2911209402 @default.
- W2600595343 hasRelatedWork W3214102163 @default.
- W2600595343 hasRelatedWork W4254190769 @default.
- W2600595343 hasVolume "30" @default.
- W2600595343 isParatext "false" @default.
- W2600595343 isRetracted "false" @default.
- W2600595343 magId "2600595343" @default.
- W2600595343 workType "article" @default.